Bio-Rad Releases Poster That Describes Transfection Of Primary and Difficult-to-Transfect CellsHERCULES, Calif., April 1, 2008 - Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced today the availability of a poster (number 07-0883) that was displayed at the Association for Biomolecular Resource Facilities Annual Meeting held in February, 2008.
In the poster, Bio-Rad demonstrates how high efficiency electroporation of several difficult-to-transfect cell lines was achieved using the parameter optimization capabilities of the Gene Pulser MXcellT electroporation system. Electroporation conditions, including optimal waveform and pulse conditions, were determined in parallel for each cell type. Results of several difficult-to-transfect cell types, including HUVEC (human umbilical vein endothelial cell), Jurkat, and mouse neuroblastoma cells (Neuro-2A) with plasmid DNA or siRNA, are shown.
Data presented in the poster shows that four-hours post electroporation with a GAPDH siRNA, HUVEC cells expressed less than 97% of GAPDH mRNA than controls transfected with scrambled siRNA. In Jurkat cells, significant silencing was also obtained (>88%) as quickly as four hours post transfection and this silencing persisted for 48 hours. Transfection of Neuro-2A cells with a fluorescently labeled siRNA followed by analysis with flow cytometry resulted in 75% transfection efficiency.
Poster 07-0883 is available either from a local Bio-Rad sales office or it may be downloaded from the Bio-Rad web site at www.bio-rad.com. For more information on optimization of electroporation parameters and conditions see Bio-Rad's technical note 5622, which can also be downloaded online.
Electroporation is a valuable tool for nucleic acid delivery because it can be used for a wide variety of cell types. Along with a general movement in the scientific community to use more medically relevant cells, new tools for electroporation have become necessary as more scientists optimize delivery of siRNA, plasmids, or other molecules into mammalian cells, in particular, primary cells and those cells that are difficult-to-transfect.
Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs approximately 6,300 people globally and had revenues approaching $1.5 billion in 2007. For more information, visit www.bio-rad.com.
For more information, please contact:
Bio-Rad Laboratories, Inc.
Posted: April 2008